Painful diabetic neuropathy: advantage of novel drugs over old drugs?
Ziegler
Dan
D
Institute for Clinical Diabetology, German Diabetes Center at the Heinrich-Heine University, Leibniz Center for Diabetes Research, Department of Metabolic Diseases, University Hospital, Düsseldorf, Germany. dan.ziegler@ddz.uni-duesseldorf.de
D000639:Amitriptyline / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use; D000982:Antipruritics / Q000627:therapeutic use; D002211:Capsaicin / Q000627:therapeutic use; D002908:Chronic Disease; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D010146:Pain / Q000145:classification / Q000503:physiopathology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D008063:Thioctic Acid / Q000627:therapeutic use
D000639:Amitriptyline; D000700:Analgesics; D000975:Antioxidants; D000982:Antipruritics; D002211:Capsaicin; D007004:Hypoglycemic Agents; D007328:Insulin; D017367:Selective Serotonin Reuptake Inhibitors; D008063:Thioctic Acid